Fosun Pharma GLP-1 tshuaj thiab Huiruida tau mus txog kev koom tes tshwj xeeb thiab daim ntawv tso cai pom zoo
Thaum Lub Kaum Ob Hlis 9, 2025, Fosun Pharma (600196. SH; 02196. HK) tshaj tawm hnub no tias nws cov chaw tswj xyuas Chongqing Yaoyou Pharmaceutical Co., Ltd. ("Yaoyou Pharmaceutical"), Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. ("Fosun" Pharmaceutical Industry Development Co., Ltd. ("Fosun" Pharmaceutical Industry Development Co., Ltd. NYSE: PFE) tau koom ua ke kos npe rau "Daim Ntawv Pom Zoo", tso cai rau Pfizer kom tsim kho, siv, tsim khoom, thiab kev lag luam thoob ntiaj teb rau qhov ncauj me me glucagon zoo li peptide-1 receptor (GLP-1 capsules) agonists (xws li VP05002) thiab cov khoom uas muaj cov khoom xyaw nquag. Daim ntawv tso cai suav nrog kev kho mob, kev kuaj mob, thiab kev tiv thaiv txhua qhov kev qhia hauv tib neeg thiab tsiaj txhu. Raws li cov lus pom zoo, Yaoyou Pharmaceutical yuav ua tiav VP05002 hauv Australia! Ua kev sim tshuaj ntsuam xyuas thiab muab cov ntawv tso cai tshwj xeeb rau Pfizer rau kev txhim kho ntxiv, tsim khoom, thiab kev lag luam thoob ntiaj teb. Yaoyou Pharmaceutical yuav tau txais cov nyiaj them poob qis ntawm $ 150 lab thiab tsim nyog tau txais kev them nyiaj tseem ceeb txog $ 1.935 billion ntsig txog kev txhim kho tshwj xeeb, kev sau npe, thiab kev lag luam tseem ceeb, nrog rau cov nqi qis dua tom qab cov khoom raug pom zoo rau kev muag khoom.
Cov molecule glucagon me me zoo li peptide-1 receptor (GLP-1R) agonist muaj ntawv tso cai lub sijhawm no yog tus kheej tsim los ntawm Yaoyou Pharmaceutical, ib lub koom haum ntawm Fosun Pharmaceutical, thiab muaj txoj cai ywj pheej ntawm kev txawj ntse. Cov kev qhia muaj peev xwm rau kev kho cov kab mob cuam tshuam nrog cov metabolism muaj xws li tab sis tsis txwv rau kev tswj qhov hnyav mus sij hawm ntev, hom 2 mob ntshav qab zib mellitus, metabolic dysfunction ntsig txog steatohepatitis (MASH) (uas yog, nonalcoholic steatohepatitis (NASH)). Tam sim no, nws nyob rau theem kho mob I hauv Australia.
Lub ntiaj teb thawj zaug! Sanofi RNAi kev kho mob Fentosiland tau pom zoo rau kev ua lag luam hauv Suav teb
Thaum Lub Kaum Ob Hlis 10, 2025, Sanofi tshaj tawm tias nws txoj kev kho RNAi, fitusiran (Suav lub npe lag luam: Sanofin, Lub npe lag luam Askiv: Qfitlia), tau txais kev pom zoo los ntawm National Medical Products Administration (NMPA) rau niaj hnub kev kho mob rau cov menyuam yaus thiab cov neeg laus hnub nyoog 12 xyoos thiab siab dua nrog cov kab mob hauv qab no los tiv thaiv los ntshav ntau los yog txo qis. tsis muaj coagulation factor V inhibitors (congenital coagulation factor VI deficiency, FVI<1%) or ② presence or absence of coagulation factors! Patients with severe hemophilia B (congenital coagulation factor | X deficiency, FIX<1%) caused by inhibitors. This product is the first RNAi therapy in the hemophilia field, requiring at least 6 injections per year.
Fentosiland yog kev kho RNA ntawm nws tus kheej tsim los ntawm Alnylam Pharmaceuticals, tsom rau antithrombin I (AT I). Thaum Lub Ib Hlis 2014, Sanofi siv $ 700 lab kom tau txais 12% ceg txheem ntseeg hauv Alnylam Pharmaceuticals, yeej muaj feem cuam tshuam txog plaub txoj kev kho RNAi suav nrog Fentosiland. Txog tam sim no, Sanofi tsuas yog tuav txoj cai rau ob yam tshuaj, Fentosilan thiab Revusiran.
Fitusiran (Suav lub npe lag luam Safine, lus Askiv lub npe Qfitlia) yog lub ntiaj teb thawj txoj kev kho mob hemophilia RNAi tsim los ntawm AlInylam Pharmaceuticals thiab txhawb nqa los ntawm Sanofi. Nws tau pom zoo los ntawm US FDA thaum Lub Peb Hlis 2025 thiab tau pom zoo rau kev ua lag luam hauv Suav teb thaum Lub Kaum Ob Hlis ntawm tib lub xyoo. Nws daim ntawv teev npe tau muab tso rau hauv Tuam Tshoj Rare Disease Drug Development Pilot Program; Cov tshuaj no tsim nyog rau cov neeg mob hemophilia A lossis B uas muaj hnub nyoog 12 xyoos thiab siab dua, txawm tias muaj lossis tsis muaj coagulation factor inhibitors hauv lub cev. Nws tuaj yeem siv rau niaj hnub tiv thaiv kev kho mob los ntawm kev tsom mus rau inhibition ntawm daim siab antithrombin ntau lawm los ntawm RNAi thev naus laus zis, rov ua kom lub cev ua haujlwm hemostatic hauv lub cev, txo qhov kev pheej hmoo ntawm kev tawm tsam los ntshav tsis tseeb, thiab siv cov tshuaj subcutaneous. Thawj koob tshuaj yog 50 milligrams txhua ob lub hlis, thiab kev siv tshuaj yuav raug kho raws li kev ua haujlwm antithrombin. Yam tsawg kawg yog 6 txhaj tshuaj nyob rau ib xyoos, uas txo qhov zaus ntawm kev tswj hwm piv rau kev kho ib txwm siv thiab muab kev kho mob yooj yim dua rau cov neeg mob hemophilia.